Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 5Endometrial Neoplasms 4Uterine Neoplasms 2Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Triple Negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcopenia 1Recurrence 1Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Malnutrition 1Genital Neoplasms, Female 1Genital Diseases, Female 1Esophageal Squamous Cell Carcinoma 1Endocrine System Diseases 1Dysgeusia 1Carcinoma, Pancreatic Ductal 1Carcinoma 1

Interventions

niraparib 2anlotinib 1Paclitaxel 1Ocoxin 1Filgrastim 1Diffusion 1Carboplatin 1CP protocol 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endocrine System Diseases × CP protocol × Gynecologic × Clear all
NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Active not recruiting
56 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡